These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 15889127)

  • 41. Influence of demographic factors and biochemical characteristics on the prostate-specific antigen (PSA) response to testosterone replacement therapy.
    Verit A
    Int J Impot Res; 2006; 18(6):574; author reply 575. PubMed ID: 17075587
    [No Abstract]   [Full Text] [Related]  

  • 42. Guilt by association: a historical perspective on Huggins, testosterone therapy, and prostate cancer.
    Morgentaler A
    J Sex Med; 2008 Aug; 5(8):1834-40. PubMed ID: 18547385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Testosterone Replacement Therapy: The Emperor's New Clothes.
    Sansone A; Sansone M; Lenzi A; Romanelli F
    Rejuvenation Res; 2017 Feb; 20(1):9-14. PubMed ID: 27124096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice.
    Shao TC; Li HL; Kasper S; Matusik R; Ittmann M; Cunningham GR
    Prostate; 2006 Mar; 66(4):369-76. PubMed ID: 16302273
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Promising research for advanced prostate cancer.
    Mayo Clin Health Lett; 2010 Jul; 28(7):4. PubMed ID: 20799378
    [No Abstract]   [Full Text] [Related]  

  • 47. Testosterone replacement therapy in male late onset hypogonadism: available pharmacological strategies.
    Turchi P; Simi S; Pescatori ES
    J Endocrinol Invest; 2005; 28(11 Suppl Proceedings):61-8. PubMed ID: 16760628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: scientific background and rationale.
    Lunenfeld B; Saad F; Hoesl CE
    Aging Male; 2005 Jun; 8(2):59-74. PubMed ID: 16096160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The pros and cons of testosterone replacement in elderly men: a panel discussion.
    Mayo Clin Proc; 2000 Jan; 75 Suppl():S88-91. PubMed ID: 10959224
    [No Abstract]   [Full Text] [Related]  

  • 51. Testosterone therapy in castrate-resistant prostate cancer: a possible new approach.
    Gardiner RA; Sweeney C; Tilley WD
    Eur Urol; 2009 Aug; 56(2):245-6. PubMed ID: 19409691
    [No Abstract]   [Full Text] [Related]  

  • 52. Male hormone use soars despite unknown risks.
    Consum Rep; 2004 Feb; 69(2):45. PubMed ID: 15000117
    [No Abstract]   [Full Text] [Related]  

  • 53. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy.
    Slater S; Oliver RT
    Drugs Aging; 2000 Dec; 17(6):431-9. PubMed ID: 11200304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical practice experience with testosterone treatment in men with testosterone deficiency syndrome.
    McLaren D; Siemens DR; Izard J; Black A; Morales A
    BJU Int; 2008 Nov; 102(9):1142-6. PubMed ID: 18540933
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Testosterone and prostate cancer: an historical perspective on a modern myth.
    Morgentaler A
    Eur Urol; 2006 Nov; 50(5):935-9. PubMed ID: 16875775
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Editorial comment on: Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.
    Sciarra A
    Eur Urol; 2009 Feb; 55(2):320-1. PubMed ID: 18838210
    [No Abstract]   [Full Text] [Related]  

  • 57. [Testosterone and prostate].
    Vaucher L; Paduch DA; Jichlinski P; Pralong F
    Rev Med Suisse; 2011 Dec; 7(320):2399-400, 2402-3. PubMed ID: 22232869
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.
    Seftel A
    Int J Impot Res; 2007; 19(1):2-24. PubMed ID: 16193074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormone replacement, the male version. Prescriptions for testosterone have soared, but is the hormone safe and effective?
    Harv Health Lett; 2004 May; 29(7):4-5. PubMed ID: 15153396
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.